Pancreatic ductal adenocarcinoma (PDA)

Pathway ID: SIGNOR-PDAP

Description: Pancreatic ductal adenocarcinoma (PDA) is the predominant form of pancreatic cancer. It is particularly heterogeneous. Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors. The overexpression of HER-2/neu and activating point mutations in the KRAS gene occur early, inactivation of the CKN2A gene (p16INK and p19ARF) at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Also RAF mutations are found, but BRAF and KRAS gene mutations are mutually exclusive. Other mutated oncogenes are AKT1 or AKT2. Other tumor suppressors: CDKN2B and FHIT.

Curated by: Luisa Castagnoli

47 Seed Entities

Organism:
Name Primary ID
Angiogenesis SIGNOR-PH46
MEK1/2 SIGNOR-PF25
E2F1 Q01094
TERT O14746
MDM2 Q00987
RB1 P06400
EGF P01133
STAT3 P40763
PI3K SIGNOR-C156
TGFA P01135
STAT1/STAT3 SIGNOR-C118
Immortality SIGNOR-PH47
SMAD2/SMAD4 SIGNOR-C8
SMAD3/SMAD4 SIGNOR-C9
SMAD2 Q15796
ErbB receptor family SIGNOR-PF36
FHIT P49789
CDKN2A P42771
NFKBIA P25963
TGFBR2 P37173
IKK-complex SIGNOR-C14
Survival SIGNOR-PH13
CyclinD1/CDK6 SIGNOR-C143
BRAF P15056
PIP3 CHEBI:16618
mTORC1 SIGNOR-C3
CDKN2B P42772
NfKb-p65/p50 SIGNOR-C13
CDK4 P11802
Apoptosis SIGNOR-PH2
Proliferation SIGNOR-PH4
Inflammation SIGNOR-PH12
SMAD4 Q13485
TGFb SIGNOR-PF5
CTNNB1 P35222
ERK1/2 SIGNOR-PF1
AP1 SIGNOR-C154
SMAD3 P84022
VEGFA P15692
CyclinD/CDK4 SIGNOR-C18
KRAS P01116
G1/S_transition SIGNOR-PH50
JAK1/STAT1/STAT3 SIGNOR-C120
TP53 P04637
EGFR P00533
AKT SIGNOR-PF24
TGFBR1 P36897